A company that says its products are backed by science yet stands to profit as science deniers in its sales force tout them as a panacea of choice harms consumers, health misinformation experts said, by pushing falsehoods along with pills
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
This phase is driven by rising interest in cellular health, detoxification, antioxidant replenishment, and endurance support
Instead, it is injected straight into the bloodstream to achieve maximum effectiveness
10, e2206771
F.BillioudV.AlbertoJ
